vs

Side-by-side financial comparison of Bloomin' Brands, Inc. (BLMN) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Bloomin' Brands, Inc. is the larger business by last-quarter revenue ($975.2M vs $622.0M, roughly 1.6× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs -1.4%, a 35.8% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 0.3%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -4.5%).

Bloomin' Brands, Inc. is a restaurant holding company that owns several American casual dining restaurant chains. The company was established in 1988 in Tampa, Florida, where it is headquartered.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

BLMN vs RPRX — Head-to-Head

Bigger by revenue
BLMN
BLMN
1.6× larger
BLMN
$975.2M
$622.0M
RPRX
Growing faster (revenue YoY)
RPRX
RPRX
+4.4% gap
RPRX
4.8%
0.3%
BLMN
Higher net margin
RPRX
RPRX
35.8% more per $
RPRX
34.4%
-1.4%
BLMN
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
-4.5%
BLMN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BLMN
BLMN
RPRX
RPRX
Revenue
$975.2M
$622.0M
Net Profit
$-13.5M
$214.2M
Gross Margin
70.2%
Operating Margin
-1.4%
62.4%
Net Margin
-1.4%
34.4%
Revenue YoY
0.3%
4.8%
Net Profit YoY
83.0%
2.9%
EPS (diluted)
$-0.16
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLMN
BLMN
RPRX
RPRX
Q4 25
$975.2M
$622.0M
Q3 25
$928.8M
$609.3M
Q2 25
$1.0B
$578.7M
Q1 25
$1.0B
$568.2M
Q4 24
$972.0M
$593.6M
Q3 24
$910.0M
$564.7M
Q2 24
$999.4M
$537.3M
Q1 24
$1.1B
$568.0M
Net Profit
BLMN
BLMN
RPRX
RPRX
Q4 25
$-13.5M
$214.2M
Q3 25
$-45.9M
$288.2M
Q2 25
$25.4M
$30.2M
Q1 25
$42.2M
$238.3M
Q4 24
$-79.5M
$208.2M
Q3 24
$6.9M
$544.0M
Q2 24
$28.4M
$102.0M
Q1 24
$-83.9M
$4.8M
Gross Margin
BLMN
BLMN
RPRX
RPRX
Q4 25
70.2%
Q3 25
70.4%
Q2 25
70.2%
Q1 25
70.1%
Q4 24
71.6%
Q3 24
71.3%
Q2 24
70.5%
Q1 24
70.5%
Operating Margin
BLMN
BLMN
RPRX
RPRX
Q4 25
-1.4%
62.4%
Q3 25
-3.9%
70.1%
Q2 25
3.0%
36.3%
Q1 25
5.5%
94.0%
Q4 24
1.7%
60.9%
Q3 24
0.9%
Q2 24
4.4%
50.2%
Q1 24
6.6%
-13.0%
Net Margin
BLMN
BLMN
RPRX
RPRX
Q4 25
-1.4%
34.4%
Q3 25
-4.9%
47.3%
Q2 25
2.5%
5.2%
Q1 25
4.0%
41.9%
Q4 24
-8.2%
35.1%
Q3 24
0.8%
96.3%
Q2 24
2.8%
19.0%
Q1 24
-7.8%
0.8%
EPS (diluted)
BLMN
BLMN
RPRX
RPRX
Q4 25
$-0.16
$0.49
Q3 25
$-0.54
$0.67
Q2 25
$0.30
$0.07
Q1 25
$0.50
$0.55
Q4 24
$-0.93
$0.46
Q3 24
$0.08
$1.21
Q2 24
$0.32
$0.23
Q1 24
$-0.96
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLMN
BLMN
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$59.5M
$618.7M
Total DebtLower is stronger
$787.4M
$9.0B
Stockholders' EquityBook value
$333.6M
$9.7B
Total Assets
$3.2B
$19.6B
Debt / EquityLower = less leverage
2.36×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLMN
BLMN
RPRX
RPRX
Q4 25
$59.5M
$618.7M
Q3 25
$66.5M
$938.9M
Q2 25
$50.3M
$631.9M
Q1 25
$57.7M
$1.1B
Q4 24
$70.1M
$929.0M
Q3 24
$83.6M
$950.1M
Q2 24
$117.9M
$1.8B
Q1 24
$131.7M
$843.0M
Total Debt
BLMN
BLMN
RPRX
RPRX
Q4 25
$787.4M
$9.0B
Q3 25
$962.2M
$8.9B
Q2 25
$917.1M
$8.0B
Q1 25
$917.6M
$7.6B
Q4 24
$1.0B
$7.6B
Q3 24
$1.1B
$7.6B
Q2 24
$1.0B
$7.6B
Q1 24
$951.8M
$6.1B
Stockholders' Equity
BLMN
BLMN
RPRX
RPRX
Q4 25
$333.6M
$9.7B
Q3 25
$344.1M
$9.6B
Q2 25
$397.2M
$9.5B
Q1 25
$380.6M
$9.8B
Q4 24
$135.5M
$10.3B
Q3 24
$242.1M
$10.3B
Q2 24
$286.8M
$9.8B
Q1 24
$302.7M
$9.9B
Total Assets
BLMN
BLMN
RPRX
RPRX
Q4 25
$3.2B
$19.6B
Q3 25
$3.3B
$19.3B
Q2 25
$3.3B
$18.3B
Q1 25
$3.3B
$17.6B
Q4 24
$3.4B
$18.2B
Q3 24
$3.4B
$18.0B
Q2 24
$3.4B
$17.7B
Q1 24
$3.4B
$16.1B
Debt / Equity
BLMN
BLMN
RPRX
RPRX
Q4 25
2.36×
0.92×
Q3 25
2.80×
0.93×
Q2 25
2.31×
0.84×
Q1 25
2.41×
0.78×
Q4 24
7.58×
0.74×
Q3 24
4.51×
0.74×
Q2 24
3.49×
0.78×
Q1 24
3.14×
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLMN
BLMN
RPRX
RPRX
Operating Cash FlowLast quarter
$119.1M
$827.1M
Free Cash FlowOCF − Capex
$63.7M
FCF MarginFCF / Revenue
6.5%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters
$96.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLMN
BLMN
RPRX
RPRX
Q4 25
$119.1M
$827.1M
Q3 25
$34.4M
$702.6M
Q2 25
$49.7M
$364.0M
Q1 25
$73.5M
$596.1M
Q4 24
$119.8M
$742.5M
Q3 24
$-7.8M
$703.6M
Q2 24
$42.4M
$658.2M
Q1 24
$73.8M
$664.6M
Free Cash Flow
BLMN
BLMN
RPRX
RPRX
Q4 25
$63.7M
Q3 25
$-5.7M
Q2 25
$11.1M
Q1 25
$27.7M
Q4 24
$66.7M
Q3 24
$-67.3M
Q2 24
$-12.1M
Q1 24
$20.0M
FCF Margin
BLMN
BLMN
RPRX
RPRX
Q4 25
6.5%
Q3 25
-0.6%
Q2 25
1.1%
Q1 25
2.6%
Q4 24
6.9%
Q3 24
-7.4%
Q2 24
-1.2%
Q1 24
1.9%
Capex Intensity
BLMN
BLMN
RPRX
RPRX
Q4 25
5.7%
Q3 25
4.3%
Q2 25
3.8%
Q1 25
4.4%
Q4 24
5.5%
Q3 24
6.5%
Q2 24
5.5%
Q1 24
5.0%
Cash Conversion
BLMN
BLMN
RPRX
RPRX
Q4 25
3.86×
Q3 25
2.44×
Q2 25
1.95×
12.06×
Q1 25
1.74×
2.50×
Q4 24
3.57×
Q3 24
-1.13×
1.29×
Q2 24
1.49×
6.45×
Q1 24
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLMN
BLMN

Food And Beverage$958.0M98%
Franchiseand Other Revenue$17.2M2%
International Franchise Segment$7.8M1%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons